HAYA Therapeutics SA

HAYA Therapeutics SA develops precise and potent RNA-guided programmable therapeutics by leveraging the power of the regulatory "dark genome." The company's technology decodes complex disease causality, targeting regulatory RNAs to address conditions driven by cell-state reprogramming. This platform allows for repeatable drug discovery, with lead programs focusing on fibrotic, metabolic, and age-related diseases.

The company was co-founded in 2017 by Daniel Blessing and Samir Ounzain, with Dr. Ounzain serving as CEO and Scientific Co-Founder. His extensive background as a molecular biologist, exploring the regulatory "dark matter" of the human genome for over two decades, provided the foundational insights. This deep scientific understanding informed HAYA's approach to unlock novel therapeutic pathways.

HAYA Therapeutics aims to serve patients afflicted with serious fibrotic, metabolic, and age-related health conditions. Their vision is to advance programmable therapeutics derived from regulatory RNAs, ultimately developing innovative precision medicines that profoundly impact disease progression and improve patient outcomes.

HAYA Therapeutics SA is a precision medicines company developing programmable RNA-guided therapeutics that target long non‑coding RNAs (lncRNAs) in the regulatory “dark” genome to treat fibrotic, metabolic, cardiovascular and age‑related diseases, with a lead program for heart failure and a platform designed for tissue‑ and cell‑selective reprogramming of pathological cell states[3][7].

High‑Level Overview

• Mission: HAYA aims to decode the regulatory genome and develop tissue‑ and cell‑selective genomic medicines that reprogram disease‑driving cell states to “program lasting health.”[7][4]
  - Investment/operational focus (for investors reading): HAYA is a platform biotech focused on lncRNA targets and RNA‑guided therapeutics, pursuing translational programs rather than acting as an investor itself[3][4].
  - Key sectors: cardiovascular (heart failure), fibrotic diseases (lungs, liver, kidneys), metabolic disorders (including obesity), and oncology microenvironments where fibrosis and cell‑state dysregulation matter[3][4].
  - Impact on the startup/biotech ecosystem: HAYA is advancing a next‑generation, computationally driven discovery platform (HAYAtlas) that accelerates target nomination and design of RNA medicines, and has attracted blue‑chip VC and industry partnerships—helping validate regulatory‑genome‑centric drug discovery as a scalable model[4][3].

Origin Story

• Founding and early financing: HAYA was founded in 2021 and completed a seed financing (reported at USD 25M) as it built its discovery engine and moved toward translational programs[6][3].
  - Founders and leadership: The company was co‑founded by Samir Ounzain, a molecular biologist with ~20 years’ experience studying regulatory non‑coding RNAs, who serves as CEO and has led the company from discovery to platform execution[6].
  - How the idea emerged: HAYA’s concept grew from research on the regulatory (non‑coding) genome and long non‑coding RNAs as master regulators of cell identity; the company built integrated multimodal functional genomics plus machine‑learning to map causal regulatory RNAs and convert them into programmable therapeutics[4][7].
  - Early traction / pivotal moments: HAYA advanced a lead candidate for heart failure (HTX‑001), opened U.S. labs, raised significant Series A capital, and secured a major collaboration with Eli Lilly (multi‑year collaboration focused on metabolic targets), signaling strong validation from both venture and pharma partners[3][6].

Core Differentiators

• Platform & target space: Focus on the regulatory “dark genome” (lncRNAs) rather than protein targets, aiming for mechanistic, cell‑state reprogramming rather than symptomatic treatment[3][7].
  - HAYAtlas & causal intelligence: Integrated multimodal functional genomics (transcriptomics, epigenomics, chromatin accessibility, long‑read sequencing) combined with proprietary computational and machine‑learning stacks to produce a causally‑informative atlas for target nomination[4].
  - Tissue/cell specificity: Engineering RNA‑guided therapeutics with the goal of tissue‑ and cell‑selective effects to maximize efficacy and reduce off‑target risks common to broader‑acting modalities[3][4].
  - Execution speed and repeatability: Company states its platform compresses timelines (goal: target→early clinical in ~3 years) and enables repeatable discovery across fibrotic, metabolic and age‑related indications[4].
  - Validation by partners and investors: Series A led by Sofinnova Partners and Earlybird with participation from Eli Lilly, plus later collaborations with Lilly and other industry support, demonstrate external confidence in the approach[3].

Role in the Broader Tech/Biotech Landscape

• Trend alignment: HAYA sits at the intersection of RNA therapeutics, functional genomics, machine learning for causal biology, and precision, cell‑state engineering—areas that have gained momentum as RNA modalities and single‑cell/long‑read technologies matured[4][7].
  - Why timing matters: Advances in sequencing (including long‑read), single‑cell profiling, and computational causal inference have made systematic decoding of non‑coding regulatory elements actionable for therapeutic design—creating an opening for lncRNA‑targeted medicines[4].
  - Market forces in their favor: Large unmet needs in heart failure, organ fibrosis and metabolic disease, combined with growing pharma interest in RNA and precision modalities, create commercial and partnership opportunities exemplified by HAYA’s Lilly collaboration[3][6].
  - Influence on ecosystem: By operationalizing a regulatory‑genome atlas and translating lncRNA biology into drug programs, HAYA helps validate a class of targets often underexplored by traditional small‑molecule or protein‑centric approaches, potentially spurring similar startups and R&D investments[4][3].

Quick Take & Future Outlook

• Near term: Expect continued advancement of HTX‑001 (heart‑failure program), expansion of the lncRNA pipeline across fibrotic and metabolic indications, and further biomarker and translational work enabled by the HAYAtlas to de‑risk clinical development[3][4].
  - Medium term: If HAYA’s platform consistently identifies causal lncRNA targets and translates them into safe, tissue‑selective RNA medicines, the company could catalyze broader adoption of regulatory‑genome targeting and attract additional big‑pharma partnerships or strategic exits[4][3].
  - Risks and shaping trends: Scientific and translational risk remains—lncRNA biology can be complex and sometimes species‑specific, and delivery/tissue‑selectivity for RNA therapeutics remains a major technical challenge—so execution and clinical readouts will be decisive[4][3].
  - Final thought: HAYA is positioning itself as a platform‑first biotech that aims to move beyond symptomatic treatment toward causal reprogramming of disease cell states; its progress and partner validation make it one to watch among companies aiming to convert the “dark genome” into a new class of medicines[7][3].